Docteur JEROME AVOUAC
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🎓 Diplômes
- DE Docteur en médecine
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
Thèses universitaires
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Direction de thèses
🎓 2 thèses dirigéesImplication des cellules MAIT (lymphocytes T invariants associés aux muqueuses) dans la polyarthrite rhumatoïde
2025Doctorant·e : Manon Lesturgie-Talarek
Immunologie🎓 Université Paris CitéImplication d'acteurs de l'angiogenèse dans l'inflammation synoviale de la polyarthrite rhumatoïde
2019Doctorant·e : Agathe Leblond
Immunologie🎓 Université Paris Cité
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Activité de recherche & publications
Source : bases de données publiques (OpenAlex, PubMed).
h-index
72
h articles cités ≥ h fois chacun. Un h de 72 = 72 publications avec 72+ citations.
Citations
17 157
Publications
547
i10-index
214
Thématiques principales
- Systemic Sclerosis and Related Diseases ×268
- Rheumatoid Arthritis Research and Therapies ×143
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis ×97
- Inflammatory Myopathies and Dermatomyositis ×61
- Systemic Lupus Erythematosus Research ×50
Affiliations FR : Inserm · Université Paris Cité · Hôpital Cochin
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Bibliographie
Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database
2026ArticleRheumatology
Hand function impairment in Systemic Sclerosis: determinants through investigations of clinical, radiographic and ultrasonographic features
2025ArticleSeminars in Arthritis and Rheumatism
French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases
2025ArticleJoint Bone Spine
Mucosal‐Associated Invariant T Cells in Rheumatic Diseases
2025ArticleArthritis & rheumatology
Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms
2025ArticleRMD Open
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
2025ArticleThe Lancet Rheumatology
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective
2025ArticleInfectious Diseases and Therapy
Erratum à « Actualisation 2024 des recommandations de la Société française de rhumatologie pour le diagnostic et la prise en charge des personnes souffrant de polyarthrite rhumatoïde » [Rev. Rhum. 2024;91 (6):663–93]
2025ArticleRevue du Rhumatisme
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Lieu de consultation
GHU APHP CUP SITE COCHIN PORT ROYAL
27 Rue DU FAUBOURG SAINT JACQUES, 75679 Paris 14e Arrondissement
☎ 0158414141Hospitalier
Tarifs & secteur de conventionnement
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Top publications · les plus citées
- 1CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
The Lancet. Rheumatology · 2025
📚 28 citations🎯 RCR 10.18 - 2Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease
RMD open · 2024
Lire l'abstract Crossref ↓
Objective To develop a multivariable model for predicting the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) over 52 weeks. Methods We used logistic regression models to analyse associations between candidate predictors assessed at baseline and progression of SSc-ILD (absolute decline in forced vital capacity (FVC) % predicted >5% or death) over 52 weeks in the placebo group of the SENSCIS trial. Analyses were performed in the overall placebo group and in a subgroup with early and/or inflammatory SSc and/or severe skin fibrosis (<18 months since first non-Raynaud symptom, elevated inflammatory markers, and/or modified Rodnan skin score (mRSS) >18) at baseline. Model performance was assessed using the area under the receiver operating characteristic curve (AUC). Results In the overall placebo group (n=288), the performance of the final multivariable model for predicting SSc-ILD progression was moderate (apparent AUC: 0.63). A stronger model, with an apparent AUC of 0.75, was developed in the subgroup with early and/or inflammatory SSc and/or severe skin fibrosis at baseline (n=155). This model included diffusing capacity of the lung for carbon monoxide (DLco) % predicted, time since first non-Raynaud symptom, mRSS, anti-topoisomerase I antibody status and mycophenolate use. Conclusion Prediction of the progression of SSc-ILD may require different approaches in distinct subgroups of patients. Among patients with SSc-ILD and early and/or inflammatory SSc and/or severe skin fibrosis, a nomogram based on a multivariable model may be of value for identifying patients at risk of short-term progression.
Publications scientifiques (50) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Transversal30
▼
Transversal30
▼- 18F-fluorodeoxyglucose PET/CT uptake characteristics in immune checkpoint inhibitor-induced polymyalgia rheumatica compared to idiopathic polymyalgia rheumatica
Rheumatology (Oxford, England) · 2026 · Journal Article
Bouchut A, Jacquet T, Gouyette Y, Herrou J, et al.
🩺 Clinique - Roads and detours for CAR T cell therapy in autoimmune diseases
Nature reviews. Drug discovery · 2026 · Journal Article
Avouac J, Barzel A, Caiati D, Davis RS, et al.
- Baseline characteristics of the TRANSLATE2 cohort: A prospective study on rheumatoid arthritis-associated interstitial lung disease
Joint bone spine · 2026 · Journal Article
Juge PA, Debray MP, Pensec VD, Richez C, et al.
- Teleconsultation for rheumatoid arthritis: A selective therapeutic tool in routine care
Joint bone spine · 2026 · Letter
Avouac J, Fogel O, Molto A, Allanore Y
- Adult-onset refractory inflammatory arthritis associated with somatic mosaicism of a truncating COPA mutation
Joint bone spine · 2026 · Letter
Avouac J, d'Alessandro R, Thomas M, Hecquet S, et al.
- Hand function impairment in Systemic Sclerosis: determinants through investigations of clinical, radiographic and ultrasonographic features
Seminars in arthritis and rheumatism · 2026 · Journal Article
Franchi G, Marazzi E, Lescoat A, Hecquet S, et al.
- Mucosal-Associated Invariant T Cells in Rheumatic Diseases
Arthritis & rheumatology (Hoboken, N.J.) · 2026 · Journal Article
Lesturgie-Talarek M, Gonzalez V, Beaudoin L, Sénot N, et al.
📚 1 cit. - [Care pathway to diagnosis in fibromyalgia and inflammatory rheumatic diseases: A patient-centered approach using a comparative mixed-methods study]
La Revue de medecine interne · 2026 · Journal Article
Harim M, Kachaner A, Combier A, Trouvin AP, et al.
- Short telomere length is associated with accelerated lung disease progression in rheumatoid arthritis-associated interstitial lung disease
The European respiratory journal · 2025 · Journal Article
El Husseini K, Lee JS, Juge PA, Ebstein E, et al.
📚 1 cit.🩺 Clinique - Response to the letter to the editor entitled "Is there room for precocious prevention in rheumatoid arthritis precision medicine?"
Seminars in arthritis and rheumatism · 2025 · Letter
Avouac J
- French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases
Joint bone spine · 2025 · Journal Article
Avouac J, Fogel O, Beydon M, Frémont GM, et al.
🩺 Clinique - Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges
Seminars in arthritis and rheumatism · 2025 · Journal Article
Avouac J, Kay J, Choy E
📚 9 cit.🎯 RCR 3.83 - Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms
RMD open · 2025 · Journal Article
Beretta M, Martin E, Fogel O, López-Medina C, et al.
- Risk factors associated with venous thromboembolism in rheumatoid arthritis in clinical practice
Clinical and experimental rheumatology · 2025 · Journal Article
Oudart F, Thomas M, Combier A, Molto A, et al.
- Comment on: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis: reply
Rheumatology (Oxford, England) · 2025 · Journal Article
Gerges E, Cauvet A, Schwarz M, Avouac J, et al.
- CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
The Lancet. Rheumatology · 2025 · Journal Article
Scherlinger M, Nocturne G, Radic M, Launay D, et al.
📚 28 cit.🎯 RCR 10.18🔬→🩺 Translationnel - CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?
Arthritis research & therapy · 2025 · Journal Article
Jouret M, Viel S, Fournier B, Benezech S, et al.
📚 6 cit.🎯 RCR 2.23 - Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis
Rheumatology (Oxford, England) · 2025 · Journal Article
Gerges E, Cauvet A, Schwarz M, Avouac J, et al.
📚 5 cit.🎯 RCR 1.97 - Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective
Infectious diseases and therapy · 2025 · Journal Article
Loubet P, Benotmane I, Fourati S, Malard F, et al.
📚 5 cit.🎯 RCR 1.94 - Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis
Scientific reports · 2025 · Journal Article
Lesturgie-Talarek M, Gonzalez V, Combier A, Thomas M, et al.
📚 2 cit. - CD19-targeting CAR-T cell treatment in patients with diffuse systemic sclerosis
The Lancet. Rheumatology · 2025 · Journal Article
Avouac J
📚 2 cit. - CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025 · Journal Article
Avouac J, Scherlinger M, Club for Innovative Immunotherapies in Immune-Mediated Inflammatory Diseases (C3I)
📚 2 cit. - 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis
Joint bone spine · 2024 · Journal Article
Fautrel B, Kedra J, Rempenault C, Juge PA, et al.
📚 10 cit.🎯 RCR 2.84🔬→🩺 Translationnel - Granulocytes and monocytes apheresis for polyarthritis in a multimorbid patient
Joint bone spine · 2024 · Letter
Thomas M, Fogel O, Al Tabaa O, Combier A, et al.
- Evaluation of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Assessing Rheumatoid Arthritis Activity in Teleconsultation
The Journal of rheumatology · 2024 · Journal Article
Avouac J, Molto A, Allanore Y
📚 3 cit.🎯 RCR 1.23🩺 Clinique - Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease
RMD open · 2024 · Journal Article
Kuwana M, Avouac J, Hoffmann-Vold AM, Smith V, et al.
📚 12 cit.🎯 RCR 2.79🔬→🩺 Translationnel - Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024 · Journal Article
Driouich JS, Cochin M, Lingas G, Luciani L, et al.
📚 2 cit. - Persistent remission of severe rheumatoid arthritis associated with myelodysplastic syndrome upon treatment with lenalidomide
Joint bone spine · 2024 · Case Reports
Carvès S, Birsen R, Avouac J
- Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts
Annals of the rheumatic diseases · 2024 · Letter
Avouac J, Hecquet S, Thomas M, Combier A, et al.
📚 1 cit. - DAS28-γGT for the prediction of major cardiovascular events in rheumatoid arthritis: results from the ESPOIR cohort
Rheumatology (Oxford, England) · 2024 · Journal Article
Dupont A, Constantin A, Soubrier M, Rincheval N, et al.
Épidémiologie & registres4
▼
Épidémiologie & registres4
▼- Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study
The Lancet. Rheumatology · 2025 · Journal Article
Hadjadj J, Wolfers A, Borisov O, Hazard D, et al.
📚 8 cit.🎯 RCR 2.98 - Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study
RMD open · 2025 · Journal Article
Triboulet F, Juge PA, Truchetet ME, Pham T, et al.
📚 6 cit.🎯 RCR 2.47🩺 Clinique - Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases
Rheumatology (Oxford, England) · 2024 · Journal Article
Thomas M, Masson M, Bitoun S, Hamroun S, et al.
📚 5 cit.🩺 Clinique - Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry
Rheumatology (Oxford, England) · 2024 · Journal Article
Faganello D, Bertrand A, Meunier P, Avouac J, et al.
📚 2 cit.
JAK inhibiteurs4
▼
JAK inhibiteurs4
▼- Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study
Rheumatology and therapy · 2026 · Journal Article
Östör A, Feist E, Sidiropoulos P, Avouac J, et al.
- Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry
Joint bone spine · 2026 · Letter
Truchetet ME, Prati C, Thevenot P, Bologna C, et al.
- Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study
Arthritis research & therapy · 2025 · Journal Article
Östör A, Feist E, Sidiropoulos P, Avouac J, et al.
📚 8 cit.🎯 RCR 3.55🩺 Clinique - Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study
The Journal of rheumatology · 2025 · Journal Article
Edwards CJ, Krönke G, Avouac J, Li Z, et al.
📚 1 cit.🩺 Clinique
Biothérapies non-anti-TNF3
▼
Biothérapies non-anti-TNF3
▼- Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial
BMJ open · 2025 · Clinical Trial Protocol
Pascart T, Fautrel B, Gottenberg JE, Ducoulombier V, et al.
🩺 Clinique - Should complete B cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis?
Rheumatology (Oxford, England) · 2024 · Journal Article
Ghossan R, Al Tabaa O, Combier A, Steelandt A, et al.
📚 4 cit.🔬→🩺 Translationnel - Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study
Rheumatology (Oxford, England) · 2024 · Journal Article
Assaraf M, Chevet B, Wendling D, Philippe P, et al.
📚 10 cit.🎯 RCR 2.81🩺 Clinique
Pharmacovigilance2
▼
Pharmacovigilance2
▼- Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series
Annals of the rheumatic diseases · 2026 · Journal Article
Scherlinger M, Dieudonné Y, Hilliquin S, Chatelus E, et al.
- The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations
Rheumatology and therapy · 2025 · Journal Article
Avouac J, Ait-Oufella H, Habauzit C, Benkhalifa S, et al.
📚 7 cit.🎯 RCR 2.82🔬→🩺 Translationnel
Revue générale2
▼
Revue générale2
▼- Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
RMD open · 2026 · Journal Article
Hilliquin S, Vismara E, Berlengiero V, Avouac J
- The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations
Rheumatology and therapy · 2025 · Journal Article
Avouac J, Ait-Oufella H, Habauzit C, Benkhalifa S, et al.
📚 7 cit.🎯 RCR 2.82🔬→🩺 Translationnel
Anti-TNF1
▼
Anti-TNF1
▼- Clinical and pharmacological outcomes after switching from intravenous to subcutaneous infliximab in chronic inflammatory rheumatic diseases
Joint bone spine · 2026 · Journal Article
Fogel O, Bottois C, Tourneur ML, Dauchez A, et al.
Arthrite juvénile1
▼
Arthrite juvénile1
▼- Intestinal barrier biomarkers in adult patients with juvenile idiopathic arthritis in transition
Joint bone spine · 2025 · Letter
Hecquet S, Thomas M, Parisel E, Combier A, et al.
Case report / série1
▼
Case report / série1
▼- Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series
Annals of the rheumatic diseases · 2026 · Journal Article
Scherlinger M, Dieudonné Y, Hilliquin S, Chatelus E, et al.
Connectivite mixte1
▼
Connectivite mixte1
▼- Nailfold videocapillaroscopy findings and associations with organ involvement in mixed connective tissue disease
Clinical and experimental rheumatology · 2025 · Journal Article
Kasser C, Boleto G, Allanore Y, Avouac J
📚 1 cit.
csDMARDs1
▼
csDMARDs1
▼- Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary
Rheumatology and therapy · 2024 · Journal Article
Taylor PC, Balsa A, Mongey AB, Filková M, et al.
📚 2 cit.🔬→🩺 Translationnel
Revue / méta-analyse1
▼
Revue / méta-analyse1
▼- Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
RMD open · 2026 · Journal Article
Hilliquin S, Vismara E, Berlengiero V, Avouac J
Sclérodermie1
▼
Sclérodermie1
▼- Deficiency and altered phenotype of mucosal-associated invariant T cells in systemic sclerosis
Journal of scleroderma and related disorders · 2024 · Journal Article
Lesturgie-Talarek M, Gonzalez V, Beaudoin L, Frantz C, et al.
📚 1 cit.
Vraie vie / RWE1
▼
Vraie vie / RWE1
▼- Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis
Seminars in arthritis and rheumatism · 2024 · Journal Article
Al Tabaa O, Hecquet S, Thomas M, Carvès S, et al.
📚 3 cit.🔬→🩺 Translationnel
